« Does Resveratrol Really Work? And Does SRT1720? |
| Back to Philadelphia »
October 11, 2010
I'm out of the lab for the next few days. It's Conference Time once again, and I'm in Philadelphia for the Fragment-Based Lead Discovery meeting. Last year this one was in England, but did I go? Nooo, I waited until it was in Philly. No offense to the city's residents who read the blog, but even its partisans would have to admit that it's not an exotic destination, particularly for someone who's lived for eight years in New Jersey like I have. Anyway, any readers of the blog who are also attending, please feel free to track me down. Bernard Munos told me last week that I look just like my picture on the site, which can't quite be true, since that's getting to be an old shot, but it's apparently a reasonable guide.
I won't be live-blogging any sessions here, although I may well mention particularly interesting things as they come up. Not everyone's into fragments, for one things, and a three-day diet of them might be a bit much. And I'm going to be busy taking notes of my own, which will necessarily be skewed by my own proprietary perspective. To be honest, seeing a blow-by-blow account of what I find interesting and what I find old hat would give away too much about what my company's up to.
But I will be blogging on other topics during the meeting, thanks to the wireless in the conference room. I take notes on the laptop, anyway, since I type much more quickly (and legibly) than I write. I've got a pen handy if I have to scrawl down a structure, but otherwise, the notes are just going into a text window. Now, that does mean that I'm going to need to find an electrical outlet somewhere in this room this afternoon. . .
+ TrackBacks (0) | Category: Chemical News
POST A COMMENT
- RELATED ENTRIES
- Mipomersen In Trouble
- LaMattina on Angell
- The Merck Index
- Asking the Tough Questions: Doomsday in the Clinic
- Don't Let the Art Director Draw Your Molecules
- Rheumatoid Arthritis Wins A Couple of Rounds
- Pfizer's Gold Dust Makes it to the WSJ
- Sue the Nobel Committee. Yeah, That'll Work.